Replies to post #243331 on Biotech Values

[DewDiligence]

I assume ENTA won't announce a partnership deal for EDP-235 before phase II is completed…

I expect ENTA to seek an FDA buy-in to run a pivotal phase-2/3 trial, instead of a straight phase-2. The FDA may not concur with such a plan, but they would (IMO) be derelict in not doing so, given the potential utility of EDP-235 in mitigating the pandemic.

If ENTA does get an FDA buy-in to run a pivotal phase-2/3, then a partnership deal up-front becomes considerably more likely, IMO.

[mouton29]

<<ENTA's EDP-235 is plainly more potent than Paxlovid.>>

Can you, or Dew (the author of the quoted statement) provide a link to comparable data for Paxlovid?